I Introduction
Although serum levels of angiotension II appear to remain relatively constant during pregnancy, the pregnant woman's ability to respond to infusion of the pressor substance is markedly diminished [1] . It is hypothesized that angiotensin converting enzyme (ACE), either through it's direct actions or it's inhibitory effect upon bracykinin, could play an important role in the development of the hypertensive disorders of pregnancy.
The precise role of ACE in the process is uncertain. Limited data are available about the rate of conversion of angiotensin I to angiotensin II or the catabolism of this decapeptide in the pregnant patient. Because vascular endothelial cells are believed to be the major site of synthesis for ACE, the marked increase in vascularity of the uterus during pregnancy would be expected to lead to increased levels of serum activity of the enzyme. Diabetes and hyperthyroidism have also been associated with elevations of serum angiotensin converting enzyme (SACE) activity [6, 10] . Similar changes in glucose/insulin and thyroid hormone dynamics that occur in the normal pregnant woman thus might also contribute to changes in SACE activity during gestation. PARENTE, et al. [8] measured SACE activity in 52 normal pregnant women at various stages of gestation. They concluded that levels during pregnancy did not change, and were consistent with those of normal non-pregnant controls. OATS, et al. [7] prospectively evaluated multiple samples for SACE activity in 18 normal primigravidae and concluded that enzyme activity was depressed during normal pregnancy, but rose as pregnancy advanced into the third tri-mester, and returned to non-pregnant levels by 6 weeks postpartum. RASMUSSEN, et al. [9] found that normotensive pregnant subjects studied during pregnancy arid 5 days post-partum had lower SACE activity compared to their own levels 3 to 6 months following delivery or to a group of non-pregnant control women.
We prospectively evaluated SACE activity in pregnant women with hypertensive disorders and diabetes in order to evaluate the test's ability to predict pregnancy induced hypertension and to understand it's role in the reninangiotensin system's dynamics. Pregnancy creates a unique environment for studying the dynamics of the renin-angiotensin system because of characteristic marked and abrupt changes in blood pressure, intravascular volume and angiotensin sensitivity. We elected to study SACE activity during the major vascular volume changes that occur in the first trimester of pregnancy, the relative vascular stability of the second and early third trimesters, the period of modest vascular constriction just prior to term, and the marked vascular readjustments of the postpartum period. Evaluation of SACE activity at 6 weeks postpartum was used as a baseline for the non-pregnant state and compared to the various gestational periods.
Materials and methods
Patients were drawn from Washington University prenatal clinics, and from the private practices of members of the full-time staff of the Department of Obstetrics and Gynecology. All patients were between the ages of 18 and 35 and gave full informed consent for participation. They were screened to exclude Sarcoidosis, Gaucher's disease, hyperthyroidism, and other disorders (with the exception of hypertension and diabetes) in which active disease may be marked by an elevation of SACE activity. The duration of pregnancy was established either by ultrasonic cephalometry or by excellent clinical dating, including a known last menstrual period, consistent first examination, early pregnancy test, and fetal heart tones at 20 weeks of gestation. The delivery dates were established by review of each patients' hospital records. Patients classified as diabetic had either a long history of type I diabetes with insulin therapy or were gestational diabetics with abnormal glucose tolerance testing in the first trimester. Chronic hypertensive patients all had elevated blood pressures (systolic greater than 130 mm Hg; diastolic greater than 90 mm Hg) prior to pregnancy and off medications. All were under therapy with at least one antihypertensive agent during the study, but none were treated with any agent that was classified as an ACE inhibitor. Blood samples were collected from pregnant patients at the specific stages of pregnancy outlined in table I. The serum was separated and immediately frozen prior to evaluation of ACE activity. All specimens were assayed within 2 weeks of collection and storage. Enzyme activity was determined by the fluorometric assay technique of FRIEDLAND and SIL-VERSTEIN [1] . This procedure measures the dipeptide hydrolysis product histidyl-leucine generated by ACE activity on the substrate hippuryl-L-histidyl-L-leucine. The histidyl-leucine is reacted under alkaline conditions with o-pthaldialdehyde and the fluorophore quantitated fluorometrically after acidification. The normal range in our laboratory (established in a mixed population of men and non-pregnant women of higher average age than the pregnant patients in this study) is 44 nM/min/ml ± 12 (1 S.D.). Mean values and standard deviations for each time interval during pregnancy and for the postpartum period were calculated and compared using the Student's t-test or Fischer's exact t-test for matched pairs.
Results
SACE activity demonstrates no significant alteration during the course of normal pregnancy, nor does it vary during pregnancies complicated by diabetes mellitus, chronic hypertension, or pregnancy-induced hypertension (PIH). Among the 112 patients studied, there were no significant differences of enzyme activity over any of the four time intervals .studied (figure 1). The combined mean SACE activity seemed to rise modestly as gestation advanced, decreased markedly in the postpartum period and rose to levels above those of pregnancy at 6 weeks postpartum. SACE activity measured 6 weeks postpartum was significantly higher for both normal and complicated patients than enzyme activity measured during pregnancy (P < 0.05). SACE activities drawn 1-3 days postpartum appeared to be lower than those during pregnancy or in the late postpartum period (P < 0.05) for all samples, but the paucity of samples within the smaller subgroups drawn at this time period precluded a mean difference having statistical significance when patients were used as their own controls in evaluating the patients with various pregnancy complications.
SACE activity at all stages of pregnancy does not differ significantly when comparing patients with chronic hypertension or pregnancy-induced hypertension to those women Figure 2 . SACE activity was evaluated in pregnancies complicated by chronic or pregnancy-induced hypertension and in pregnancies complicated by diabetes mellitus. There was no significant difference in SACE activity between any of these groups and a population of control women at any stage of pregnancy or postpartum. Results are expressed as mean ± 1 standard deviation. with a normal pregnancy (figure 2). Pregnant diabetics as a group displayed higher mean SACE activity at most stages of gestation than the normal control population (figure 3) although these differences failed to reach statistical significance. The presence of microvascular disease was not a good predictor of elevated SACE activity among diabetic pregnant patients. Similarly, fetal macrosomia, White's classification, or insulin requirement did not predict those women with increased activity (table II) .
Discussion
ACE is a COOH-terminal peptidyl dipeptide hydrolase responsible for the physiological conversion of angiotensin-I to biologically active angiotensin II. Because of the central role of the renin-angiotensin system in hypertensive disorders of pregnancy, we evaluated SACE activity in 112 pregnant women in a prospective fashion. In a population of normal pregnant women, SACE levels decreased slightly from non-pregnant values and remained relatively stable throughout the remainder of gestation. The immediate postpartum period was accompanied by a decrease in SACE activity when compared to pregnant levels. SACE activity during pregnancy complicated by chronic hypertension or by pregnancy-induced hypertension was not different than the normal pregnant population.
Because diabetes has been suggested as a possible cause of elevations of SACE activity, we also prospectively surveyed a population of pregnant diabetic women. LIEBERMAN and SAS-TRE [6] studied a heterogeneous population of males and non-pregnant females with diabetes and were able to demonstrate an increase in mean enzyme activity compared to non-diabetic control subjects. They related this elevation to the presence of microvascular disease. SACE levels in the pregnant diabetic patients we studied were slightly higher than our normal population (figure 3) but demonstrated similar Table Π . Examination of the clinical characteristics of diabetic pregnant women in whom SACE activity is greater than two standard deviations above the mean for normal pregnancy fails to reveal a consistent pattern of macrosomia or small vessel disease. Classification of diabetes in pregnancy follows WHITE'S criteria [11] . Normal values for hemoglobin A1C in our laboratory are less than 8.5%. N. D. signifies test not performed. (table II) failed to reveal a factor or factors responsible for the rise in SACE activity when compared to the group of diabetic women with levels comparable to those in the normal population. It is possible that, as suggested by other authors [3] , the elevation of SACE activity in these patients may be related to proliferation of non-vascular tissues and to generalized vasodilation.
The decrease in SACE activity in the 2 -3 days following pregnancy which we observed is consistent with decreases in other components of the renin-angiotensin system (plasma renin activity, angiotensin II, and aldosterone) in the immediate postpartum period [3] . We believe that the slight decrease in SACE activity in pregnancy when compared to the non-pregnant state and particularly the drop in enzyme activity during the first days postpartum, may represent an important step in the vasodilation of early pregnancy and the puerperium. Because ACE is known to catalyze the inactivation of the potent vasodilator bradykinin [4] , it is possible that the removal of converting-enzyme inhibition of bradykinin activity may be linked in some regulatory fashion to a variety of physiologic vasodilatory processes that occur in the puerperium.
Our results suggest that SACE activity levels are unaffected by hypertension in the pregnant patient. This seems to be true regardless of the etiology of the blood pressure increase. LEE and TODD [5] measured SACE activity in ten women with positive supine pressor tests and seven normotensive controls. They found SACE activity in those patients with a positive rollover test to be significantly higher than in the normo tensive group. Our results suggest that pregnancy-induced hypertension can be neither predicted nor diagnosed by measurement of SACE activity. We further conclude that although serum angiotensin-converting enzyme activity is somewhat responsive to pregnancy (including immediate postpartum events) it is unlikely that changes in this aspect of reninangiotensin dynamics play a causative role in the pathophysiology of either acute or chronic hypertensive processes during pregnancy.
Abstract
Angiotensin-converting enzyme occupies a central position in the dynamics of the renin-angiotensin system. We prospectively studied serum angiotensin-converting enzyme activity in 112 women at various stages of pregnancy and in the postpartum period because converting enzyme levels have not been well documented in pregnant women with medical disorders which might be expected to influence intravascular volume or blood pressure. Enzyme activity is lower during pregnancy than it is in the same population at 6 weeks postpartum. Levels of serum angiotensin converting enzyme activity remain relatively stable during gestation but drop during the immediate postpartum period. Diabetes, chronic hypertension, and pregnancy induced hypertension fo not markedly change serum angiotensin converting enzyme activity.
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Zusammenfassung

Angiotensin-Converting-Enzym im Serum bei normaler and risikobehafteter Schwangerschaft
Im Renin-Angiotensin-System nimmt das Angiotensin- Figure 3 ) mais ils suivent les memes evolutions au cours et apres la grossesse. Cette elevation des taux moyens de S. A. C. E., peut etre liee presque entierement ä une sous population de femmes diabetiques dont l'activite S. A. C. E. est nettement elevee au-dessus de la moyenne de 2 deviations Standards quel que soit les stades du la grossesse, etudies. L'analyse de la nature du diabete et de ses complications dans ce groupe de femmes (tableau I) ne permet pas de mettre en evidence un ou plusieurs facteurs responsables de l'elevation de l'activite S. A. C. E., lorsque on le compare au groupe de femmes diabetiques dont les taux sont comparables a ceux de la population normale. Nos resultats suggerent que l'hypertension induite par la grossesse ne peut etre ni predite, ni diagnostiquee par la mesure de l'activite S.A.C.E. Nous concluons egalement que bien que l'activite serique de Fenzyme de conversion de l'angiotensine soit en quelque Sorte sensible ä la grossesse (en encluant le post-partum immediat) il est improbable que les modifications du syteme renineangiotensine ä ce niveau jouent un role causal dans la physiopathologie de la maladie hypertensive de la grossesse qu'elle soit aigue ou chronique.
Mots-cles:
Activite serique de Fenzyme de conversion de l'angiotensine, diabete et grossesse, hypertension induite par la grossesse.
